Literature DB >> 25600630

Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the University of Southern California/Van Nuys (USC/VNPI) prognostic index.

Melvin J Silverstein1, Michael D Lagios.   

Abstract

The University of Southern California/Van Nuys Prognostic Index (USC/VNPI) is an algorithm that quantifies five measurable prognostic factors known to be important in predicting local recurrence in conservatively treated patients with ductal carcinoma in situ (DCIS) (tumor size, margin width, nuclear grade, age, and comedonecrosis). With five times as many patients since originally developed, sufficient numbers now exist for analysis by individual scores rather than groups of scores. To achieve a local recurrence rate of less than 20% at 12 years, these data support excision alone for all patients scoring 4, 5, or 6 and patients who score 7 but have margin widths ≥3 mm. Excision plus RT achieves the less than 20% local recurrence threshold at 12 years for patients who score 7 and have margins <3 mm, patients who score 8 and have margins ≥3 mm, and for patients who score 9 and have margins ≥5 mm. Mastectomy is required for patients who score 8 and have margins <3 mm, who score 9 and have margins <5 mm and for all patients who score 10, 11, or 12 to keep the local recurrence rate less than 20% at 12 years. DCIS is a highly favorable disease. There is no difference in mortality rate regardless of which treatment is chosen. The USC/VNPI is a numeric tool that can be used to aid the treatment decision-making process.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  DCIS; ductal carcinoma in situ; noninvasive breast cancer

Mesh:

Year:  2015        PMID: 25600630     DOI: 10.1111/tbj.12368

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  16 in total

Review 1.  Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions.

Authors:  Lawrence J Solin
Journal:  Curr Oncol Rep       Date:  2019-03-05       Impact factor: 5.075

Review 2.  De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer.

Authors:  E Shelley Hwang; Lawrence Solin
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 44.544

3.  A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma In Situ.

Authors:  Michael S Toss; Guanhao Wei; Jaspreet Kaur; Karuna Mittal; Da Hoon Choi; Brian D Melton; Remus M Osan; Islam M Miligy; Andrew R Green; Emiel A M Janssen; Håvard Søiland; Keerthi Gogineni; Upender Manne; Padmashree Rida; Emad A Rakha; Ritu Aneja
Journal:  Clin Cancer Res       Date:  2020-01-14       Impact factor: 12.531

4.  DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS.

Authors:  Eileen Rakovitch; Sameer Parpia; Anne Koch; Laval Grimard; Hany Soliman; Christiaan Stevens; Francisco Perera; Iwa Kong; Senti Senthelal; Margaret Anthes; Ericka Wiebe; Jeffrey Cao; Mira Goldberg; Sally Smith; Luciana Spadafora; Timothy J Whelan
Journal:  Breast Cancer Res Treat       Date:  2021-04-08       Impact factor: 4.872

5.  Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.

Authors:  Michael J Campbell; Frederick Baehner; Tess O'Meara; Ekene Ojukwu; Booyeon Han; Rita Mukhtar; Vickram Tandon; Max Endicott; Zelos Zhu; Jasmine Wong; Gregor Krings; Alfred Au; Joe W Gray; Laura Esserman
Journal:  Breast Cancer Res Treat       Date:  2016-10-26       Impact factor: 4.872

Review 6.  Prediction Models and Decision Aids for Women with Ductal Carcinoma In Situ: A Systematic Literature Review.

Authors:  Renée S J M Schmitz; Erica A Wilthagen; Frederieke van Duijnhoven; Marja van Oirsouw; Ellen Verschuur; Thomas Lynch; Rinaa S Punglia; E Shelley Hwang; Jelle Wesseling; Marjanka K Schmidt; Eveline M A Bleiker; Ellen G Engelhardt
Journal:  Cancers (Basel)       Date:  2022-07-02       Impact factor: 6.575

7.  Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ.

Authors:  Dean A Shumway; Chandler M McLeod; Monica Morrow; Yun Li; Allison W Kurian; Aaron Sabolch; Ann S Hamilton; Kevin C Ward; Steven J Katz; Sarah T Hawley; Reshma Jagsi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-01-09       Impact factor: 8.013

8.  Screen-detected ductal carcinoma in situ found on stereotactic vacuum-assisted biopsy of suspicious microcalcifications without mass: radiological-histological correlation.

Authors:  Bartlomiej Szynglarewicz; Piotr Kasprzak; Przemyslaw Biecek; Agnieszka Halon; Rafal Matkowski
Journal:  Radiol Oncol       Date:  2016-04-23       Impact factor: 2.991

9.  Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial.

Authors:  Mangesh A Thorat; Pauline M Levey; J Louise Jones; Sarah E Pinder; Nigel J Bundred; Ian S Fentiman; Jack Cuzick
Journal:  Clin Cancer Res       Date:  2021-03-16       Impact factor: 12.531

10.  Breast segmentectomy with rotation mammoplasty as an oncoplastic approach to extensive ductal carcinoma in situ.

Authors:  Bartlomiej Szynglarewicz; Adam Maciejczyk; Jozef Forgacz; Rafal Matkowski
Journal:  World J Surg Oncol       Date:  2016-03-09       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.